Axon Enterprise (NASDAQ:AXON) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Axon Enterprise (NASDAQ:AXON) from a hold rating to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on the stock. UBS Group decreased their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Craig Hallum restated a “buy” rating and issued a $820.00 target price on shares of Axon Enterprise in a report on Wednesday, February 25th. Needham & Company LLC decreased their price target on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a report on Friday, February 20th. Royal Bank Of Canada decreased their price target on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. lifted their price objective on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $712.75.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $398.44 on Tuesday. The business’s 50 day simple moving average is $421.95 and its 200 day simple moving average is $506.34. Axon Enterprise has a one year low of $339.01 and a one year high of $885.91. The stock has a market capitalization of $32.11 billion, a PE ratio of 160.02, a PEG ratio of 7.13 and a beta of 1.44. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue was up 33.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.47 EPS. As a group, research analysts forecast that Axon Enterprise will post 1.82 earnings per share for the current year.

Insider Activity at Axon Enterprise

In related news, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the transaction, the insider owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer directly owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. This represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,855 shares of company stock worth $7,109,828 over the last ninety days. 4.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently made changes to their positions in the stock. Arkadios Wealth Advisors raised its stake in Axon Enterprise by 3.5% during the 1st quarter. Arkadios Wealth Advisors now owns 3,792 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 127 shares during the period. EverSource Wealth Advisors LLC grew its stake in Axon Enterprise by 10.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,736 shares of the biotechnology company’s stock valued at $737,000 after acquiring an additional 162 shares during the period. Empowered Funds LLC grew its stake in Axon Enterprise by 90.1% in the first quarter. Empowered Funds LLC now owns 6,320 shares of the biotechnology company’s stock valued at $2,684,000 after acquiring an additional 2,996 shares during the period. Evelyn Partners Investment Management LLP increased its holdings in shares of Axon Enterprise by 42.6% during the first quarter. Evelyn Partners Investment Management LLP now owns 1,550 shares of the biotechnology company’s stock valued at $658,000 after acquiring an additional 463 shares in the last quarter. Finally, Evelyn Partners Investment Management Services Ltd increased its holdings in shares of Axon Enterprise by 18.6% during the first quarter. Evelyn Partners Investment Management Services Ltd now owns 862 shares of the biotechnology company’s stock valued at $366,000 after acquiring an additional 135 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s Connected Devices segment is benefiting from strong demand for TASERs, body cameras, and counter-drone products, reinforcing the company’s revenue growth story. Strength in Connected Devices Unit Drives Axon: Can the Momentum Sustain?
• Positive Sentiment: The company is highlighting AI and drone growth as part of its strategy to become a broader “operating system” for public safety, which could expand long-term recurring revenue opportunities. Axon Enterprise touts AI, drone growth in push to be public safety’s operating system
• Positive Sentiment: Investors are also reacting to Axon’s strong Q1 2026 results, which included revenue of $807.35 million and higher full-year revenue growth guidance of 30%–32%, signaling sustained momentum. Should Axon’s Strong Q1 2026 Results and Higher Guidance Require Action From Axon Enterprise (AXON) Investors?
• Neutral Sentiment: Axon’s presentation at the J.P. Morgan Technology, Media and Communications Conference kept management’s growth story in front of investors, but the item itself did not include a major new catalyst. Axon Enterprise, Inc. Presents at J.P. Morgan Conference Transcript
• Neutral Sentiment: Commentary from Jim Cramer framed AXON as a high-multiple stock that may remain sensitive to bond yields and market sentiment, which is a reminder of valuation risk rather than a direct company-specific negative. Jim Cramer on Axon: “I Still Think That This Market Does Not Like High Multiple Stocks”
• Negative Sentiment: One market report noted AXON underperformed some competitors despite gains, suggesting investors may be weighing its rich valuation against the strong growth outlook. Axon Enterprise Inc. stock underperforms Monday when compared to competitors despite daily gains

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.